The stock is already down about 15% in 2023 as the pharmaceutical giant gets set to report earnings.
Here's how we'd play the stock of this pet healthcare name.
The charts suggest a bit of caution may be needed in the days ahead. Let's take a look.
A rally in the shares stalled around $180 in December and early January.
These stocks are displaying bearish tendencies based on their technical patterns.
Let's see how to trade GlycoMimetics, a clinical-stage drug developer focused on a type of cancer treatment.
We have two price target areas for this biopharmaceutical firm.
Let's check the charts on this clinical stage drug developer.
Let's check the charts and indicators.
Wednesday morning will bring traders, investors, Romans, and countrymen more macroeconomic results than they could ever wanted to peruse at one time.